Blood samples for sugar analysis were obtained whenever possible before and after the intramuscular administration of 1 mg. of crystalline glucagon. ¶ The patients' symptoms and their response to ...
Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...
The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.
FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...
Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...
Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures,” said Kevin McCulloch, President and COO of Xeris. “American Regent is the ...
Pharmaceutical Technology on MSN8d
Opko and Entera focus on oral care for obesity and metabolic disordersOpko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...
Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback